MannKind (MNKD) Scheduled to Post Quarterly Earnings on Monday
MannKind (NASDAQ:MNKD) is set to issue its Q214 quarterly earnings data on Monday, August 11th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. During the same quarter in the previous year, the company posted ($0.15) earnings per share. On average, analysts expect MannKind to post $-0.36 EPS for the current fiscal year and $-0.26 EPS for the next fiscal year.
MannKind (NASDAQ:MNKD) opened at 8.125 on Friday. MannKind has a 1-year low of $3.80 and a 1-year high of $11.48. The stock has a 50-day moving average of $9.55 and a 200-day moving average of $7.39. The company’s market cap is $3.071 billion.
A number of research firms have recently commented on MNKD. Analysts at ISI Group downgraded shares of MannKind from a “buy” rating to a “hold” rating in a research note on Tuesday, July 1st. They now have a $11.00 price target on the stock, up previously from $10.00. On a related note, analysts at MLV & Co
downgraded shares of MannKind from a “buy” rating to a “hold” rating in a research note on Tuesday, July 1st. They now have a $11.00 price target on the stock, up previously from $10.00. They noted that the move was a valuation call. Finally, analysts at Brinson Patrick raised their price target on shares of MannKind from $12.00 to $15.00 in a research note on Monday, June 30th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $9.93.
MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.